NASDAQ:BCTX Briacell Therap (BCTX) Stock Price, News & Analysis $3.01 -0.08 (-2.59%) Closing price 11/3/2026 04:00 PM EasternExtended Trading$3.01 0.00 (0.00%) As of 11/3/2026 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Briacell Therap Stock (NASDAQ:BCTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Briacell Therap alerts:Sign Up Key Stats Today's Range$2.98▼$3.1850-Day Range$3.01▼$4.3252-Week Range$2.60▼$13.09Volume52,806 shsAverage Volume58,571 shsMarket Capitalization$26.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its research is centered on treatments designed to stimulate a patient’s immune system to recognize and attack tumor cells, with an emphasis on advanced breast cancer and other solid tumors. The company’s lead technology includes Bria-IMT, an off-the-shelf, whole-cell immunotherapy derived from a breast cancer cell line. BriaCell has also been developing Bria-OTS, a personalized immunotherapy approach intended to match treatment with a patient’s human leukocyte antigen profile. Its programs have been evaluated in combination with immune checkpoint inhibitors and other therapies in clinical studies involving patients with metastatic breast cancer. BriaCell Therapeutics is listed on the Nasdaq Capital Market under the symbol BCTX and on the Toronto Stock Exchange under the symbol BCT. The company is led by William V. Williams, M.D., who serves as president and chief executive officer. Its activities are primarily focused on biotechnology research, clinical development and advancing oncology treatments through regulatory and clinical testing.AI Generated. May Contain Errors. Read More Briacell Therap Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreBCTX MarketRank™: 0.105554822535 of 5 starsBriacell Therap scored higher than 2% of companies evaluated by MarketBeat, and ranked 893rd out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBriacell Therap has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBriacell Therap has only been the subject of 1 research reports in the past 90 days.Read more about Briacell Therap's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Briacell Therap is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Briacell Therap is -0.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBriacell Therap has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.14% of the float of Briacell Therap has been sold short.Short Interest Ratio / Days to CoverBriacell Therap has a short interest ratio ("days to cover") of 14.24, which indicates bearish sentiment.Change versus previous monthShort interest in Briacell Therap has recently increased by 1.33%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBriacell Therap does not currently pay a dividend.Dividend GrowthBriacell Therap does not have a long track record of dividend growth. News and Social Media3.2 / 5News SentimentN/A News SentimentBriacell Therap has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Briacell Therap this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Briacell Therap to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Briacell Therap insiders have not sold or bought any company stock.Percentage Held by Insiders0.74% of the stock of Briacell Therap is held by insiders.Percentage Held by Institutions15.42% of the stock of Briacell Therap is held by institutions.Read more about Briacell Therap's insider trading history. Receive BCTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Briacell Therap and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCTX Stock News HeadlinesBriaCell Announces Biomarker Findings In Metastatic Breast Cancer Study, Stock Up In Pre-MarketOctober 23, 2026 | rttnews.comBriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast CancerOctober 23, 2026 | globenewswire.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets. | Weiss Ratings (Ad)BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual MeetingOctober 6, 2026 | globenewswire.comData Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer StudySeptember 14, 2026 | markets.businessinsider.comData Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer StudySeptember 14, 2026 | globenewswire.comBriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer CenterSeptember 8, 2026 | globenewswire.comBriaCell shares turn volatile after melanoma vaccine development milestoneAugust 24, 2026 | msn.comSee More Headlines BCTX Stock Analysis - Frequently Asked Questions How have BCTX shares performed this year? Briacell Therap's stock was trading at $7.11 at the start of the year. Since then, BCTX shares have decreased by 57.7% and is now trading at $3.01. How were Briacell Therap's earnings last quarter? Briacell Therap (NASDAQ:BCTX) posted its quarterly earnings results on Wednesday, October, 28th. The company reported ($1.50) EPS for the quarter. When did Briacell Therap's stock split? Briacell Therap's stock reverse split before market open on Tuesday, August 26th 2025.The 1-10 reverse split was announced on Tuesday, August 5th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Briacell Therap IPO? Briacell Therap (BCTX) raised $15 million in an IPO on Wednesday, February 24th 2021. The company issued 3,300,000 shares at $4.25-$5.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. Who are Briacell Therap's major shareholders? Top institutional shareholders of Briacell Therap include Iridian Asset Management LLC CT (0.75%). View institutional ownership trends. How do I buy shares of Briacell Therap? Shares of BCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Briacell Therap own? Based on aggregate information from My MarketBeat watchlists, some other companies that Briacell Therap investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Energy Transfer (ET), Arista Networks (ANET), Eli Lilly and Company (LLY) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings10/28/2026Today11/03/2026Fiscal Year End7/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BCTX's financial health is in the Red zone, according to TradeSmith. BCTX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCTX CIK1610820 Webwww.briacell.com Phone(604) 921-1810Fax604-921-1898Employees16Year Founded2004Profitability EPS (Trailing Twelve Months)($9.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.90 million Net MarginsN/A Pretax MarginN/A Return on Equity-178.17% Return on Assets-143.77% Debt Debt-to-Equity RatioN/A Current Ratio2.76 Quick Ratio2.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / Book1.68Miscellaneous Outstanding Shares8,730,000Free Float8,667,000Market Cap$26.28 million OptionableNo Data Beta1.26 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:BCTX) was last updated on 11/3/2026 by MarketBeat.com Staff. From Our PartnersFinancial Legend: “Big trouble ahead …”Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution ri...Weiss Ratings | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just sig...The Tomorrow Investor | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Briacell Therap Please log in to your account or sign up in order to add this asset to your watchlist. Share Briacell Therap With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
